Breaking: Galera Therapeutics Tumbles on FDA Setback
- August 09th, 2023
- 261 views
Shares of Galera Therapeutics, Inc.? (Nasdaq: GRTX) plunged over 70% in after-hours trading as the company received a Complete Response Letter (CRL) from the FDA, addressing its New Drug Application (NDA) for avasopasem manganese, a potential treatment for severe oral mucositis in head and neck cancer patients undergoing standard-of-care treatment.
The FDA's communication cited insufficiency in data from the Phase 3 ROMAN trial and supporting GT-201 trial to establish avasopasem's effectiveness and safety. An additional clinical trial will be required for resubmission.
In response, Galera stated its intention to request a Type A meeting with the FDA and outlined plans to enhance financial stability by cutting its workforce by approximately 70%.
$GRTX was trading at $0.38 in after-hours, down $1.85 (-82.59%) following the announcement.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Micron Technology, Jabil, and Birkenstock Earnings Preview: What to Expect
December 15th, 2024Upcoming Earnings: Synopsys, AeroVironment, and nCino in Focus
December 01st, 2024Countdown to Earnings: Salesforce, Marvell Technology, and Okta Take the Stage
December 01st, 2024Fluence Energy, Agilent Technologies, and Woodward Earnings On Deck: A Preview
November 24th, 2024Earnings Preview: Walt Disney, Applied Materials, and Celcuity Take Center Stage
November 11th, 2024
Member Login